Laser, anybody who knows about melanoma (and I do) knows that a stage III disease (in particular in transit disease) is very different from stage IV (metastatic disease) Electroporation is a technique also used to deliver chemotherapy to the in transit and/or cutaneous or locally advance lesions, and it is very effective. It is a technique used quite frequently when surgery cannot be used.
But stage IV is a completely different story. Untreated stage 3 and stage 4 disease have completely different 5 year survival rates (avg 50% for stage 3 and 5% for stage 4). Comparing IDRA and DVAX trial results vs ONCS is very wrong.
ONCS treatment should be compared to electrochemotherapy. See a link below
Is there any layman's way to sum this up for investors like myself who are medical language challenged? Would be appreciated :). Why are investors feeing fooled or not fooled?
Market Data 
Markets 
AI
